Hypophysitis nivolumab clinical trials - Two Pivotal Opdivo (nivolumab) Trials Show Three-Year
Across clinical trials of nivolumab administered at doses 3 mg/kg and 10 mg/kg, Grade 2 or 3 hypophysitis; Grade 3 hyperglycemia in type 1 diabetes;
Combined nivolumab and ipilimumab versus hypophysitis in one most of which are early phase clinical trials without long-term follow-up of the patients
SubacuteCNSDemyelinationafterTreatmentwith Nivolumab for Melanoma Data accumulating from clinical trials suggest the while hypophysitis, hepatitis,
Professional guide for Nivolumab. Includes: Hypophysitis (grade 2 or 3); across several clinical trials.
Melanoma metastatic nivolumab; inhibitor immunotherapy although the incidence reported with nivolumab was less than 1% in clinical trials. Hypophysitis
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives FDA Approval for the Treatment of Hepatocellular Carcinoma Patients Previously Treated with Sorafenib